Secukinumab biosimilar (CSPC Pharmaceutical Group)

司库奇尤单抗生物类似药（石药集团）

Report date: 2025/03/26 20:01:25

Base Information

Drug NameSecukinumab biosimilar (CSPC Pharmaceutical Group)
Drug Alias NameSYS6012SYS-6012
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionInterleukin 17A inhibitors
TargetsInterleukin 17A
Therapy Area/IndicationsPlaque psoriasis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesCSPC Pharmaceutical Group Ltd
China Registration ClassN/A

Develop Information

Active CompaniesCSPC Pharmaceutical Group LtdJushi Biopharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsPlaque psoriasis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A